#SABCS24 Day 3 Highlights #CommunityOnc:

1. #EUROPA: ET vs XRT HR+ ≥70 yrs @Icro_Meattini

2. #PATINA: CDK4/6i HR+ HER2+ @DFCI_BreastOnc new SoC

3. #COMET: DCIS

4. #SUPREMO: XRT post mastectomy

5. #INSEMA: ALNBx early disease

@SABCSSanAntonio @AACR @UTHealthSAMDA

1/6 1. #EUROPA: Ph III, ET vs XRT after
surgery in ≥70 yrs HR+ luminal A-like early breast cancer. Median F/U: 2yrs

- Treatment-related AEs ⬇️ w/ XRT (67% vs 85%)
- ET was associated with a greater reduction in HRQOL but we need longer data for disease control

2/6

https://twitter.com/jenniferplichta/status/1867227161268257234

#SABCS24 Day 2 Highlights #CommunityOnc:

1. #EMBER3: Oral SERD in HR+

2. #OlympiA: PARPi in gBRCA

3. #Surgery in gBRCA

#bcsm @SABCSSanAntonio #OncTwitter #MedTwitter @UTHealthSAMDA @AACR 1. #EMBER3: Ph III, #Imlunestrant +/-#Abemaciclib in HR+ advanced BC @jhaveri_komal 👏👏

- Imlunestrant alone for mESR1(mPFS: 5.5mos vs 3.8mos)
- Combo⬆️ mPFS w/all comers (9.4mos vs 5.5mos), regardless of CDK4/6 exposure
- If co-PIK3CA, Capi or this combo? @DrHBurstein
2/4

https://twitter.com/ptarantinomd/status/1866872546987217386

#SABCS24 Day 1 Highlights #CommunityOnc:

1. @FDAOncology Reviews recent approvals: #Ribociclib & #Inavolisib

2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L

3. #DB06: HR+ TDXd

4. #KN522: biomarker analysis

@SABCSSanAntonio @AACR #bcsm #OncTwitter

1/5 1. Recent @US_FDA approvals:

a). #NATALEE: Adj #Ribociclib in HR+ Stg IIA - III, 400mg 3wks on, 1wk off for 3yrs. 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS

b). #INAVO120: Inavolisib + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ mBC. PFS 15.0 vs 7.3mos (HR 0.43)

2/5

#ASH24 Highlights #CommunityOnc:

#Lymphoma
1. #POLARIX DLBCL
2. #inMIND FL
3. #TRIANGLE & #EA4151 MCL
4. #ENRICH MCL

#Myeloma
5. #AQUILA
6. Quad MetaAnalysis 1L
7. IVIG w/ BispecificAbs
8. #CARTITUDE4

#ITP
9. #LUNA3

@ASH_hematology #lymsm #mmsm #HemeTwitter 1/10 1. #POLARIX: 5yr update Pola-RCHP SoC R-CHOP (polatuzumab was approved in April 2023):

- PFS: 65% vs 59% (HR: 0.77)
- NO OS difference
- ORR/CR better in ABC/non-GCB type in R/R settings.
- Are you going to use Pola in 1L? All comers? Non-GCB? Only in R/R?

2/10

https://twitter.com/eddie_cliff/status/1865816722701459468

#WCLC24 Highlights #CommunityOncology:

1. #HARMONi2 in mNSCLC

2. #CM77TvsCM816 resectable NSCLC

3. #TROPIONLung01 in 2L mNSCLC

4. #SKIPPirr: AEs for Amivantamab

5. #TNM staging: 9th Ed

6. Personal highlights

#lcsm #OncTwitter @IASLC

1/7 1. #HARMONi2: 1L #ivonescimab (PD1/VEGF bispecific) mNSCLC PDL1 ≥ 1% vs Pembro alone.

- mPFS of 11.14 vs 5.8 mos
- ⬆️ PFS for PDL1 ≥ 50% (HR: 0.46)
- ⬆️ PFS for PDL1 1-49% (HR: 0.54), but SoC is Pembro + Chemo (🚫 single agent Pembro)
- 🇨🇳 only study, will need 🌎 study

2/7

https://twitter.com/drriyazshah/status/1832807001229054376

Day 3 #GI23 Highlights #CommunityOncology

1. #MOUNTAINEER: Tucat+Trast approved CRC

2. #SUNLIGHT: TAS102+Bev confirmed late option CRC

3. #E2211: Cape+Tem in pNET manuscript

4. #ctDNA kinetics CRC

5. TNT state in RectalCA

@ASCO #OncEd #MedEd @OncoAlert #GISM #MedTwitter 1. #MOUNTAINEER: Tucatinib + Trastuzumab now @US_FDA approved for RAS WT, HER2+ve mCRC that has progressed on upfront chemo:

- ORR 38%
- mDOR 12.4mos
- Common AEs: diarrhea, fatigue, rash, and pyrexia.

https://x.com/pashtoonkasi/status/1616413330926886912

#WCLC22 Highlights #CommunityOncology perspective:

1. #YESS Study - @RachM_UoN

2. #IMPower010 Update

3. #CALGB140503 - Sublobar resection

4. #SHAWL Study - @NarjustFlorezMD @jillfeldman4

5. #NADIM2 Trial by @MARIANOPROVENCI

1/6

#LCSM #MedTwitter @OncoAlert #OncEd @IASLC 1. #YESS Study @RachM_UoN: Lung CA screening with smoking cessation intervention concurrently:

- Smoking cessation is one of the most effective way to reduce lung CA mortality
- 33% quit at 3 months
- Women more likely to benefit

2/6